EWA-401

N/A

Report date: 2024/09/26 15:33:59

Base Information

Drug NameEWA-401
Drug Alias NameZFP-TherapeuticsVZ+434-P65VEGF ZFP +434Zinc finger DNA binding protein - SangamoEW-A-401 +[6] 
ClassificationCell and gene therapy > Gene therapy > Plasmid
Mechanisms of ActionGene transferenceVascular endothelial growth factor A stimulants
TargetsVascular endothelial growth factor A
Therapy Area/IndicationsIntermittent ClaudicationArteriosclerosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesSangamo Biosciences
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNational Heart, Lung, And Blood Institute (Nhlbi)
Active IndicationsN/A
Inactive IndicationsIntermittent ClaudicationArteriosclerosis

Other Information

ATC CodeN/A
Related LinksDrugBank